SEC Form S-8 filed by Ionis Pharmaceuticals Inc.
Delaware
|
33-0336973
|
|
(State of Incorporation)
|
(I.R.S. Employer Identification No.)
|
Large accelerated filer ☒
|
Accelerated filer ☐
|
Non-accelerated filer ☐
|
Smaller reporting company ☐
|
Emerging growth company ☐
|
Item 3. |
Incorporation of Documents by Reference.
|
(a) |
the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the Commission on February 19, 2025, and the information specifically incorporated by reference into the Registrant’s
Annual Report on Form 10-K for the year ended December 31, 2024, from the Registrant’s Definitive Proxy Statement on Schedule 14A, as filed with the Commission on April 25, 2025;
|
(b) |
the Registrant’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2025, as filed with the Commission on April 30, 2025 and Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, as filed with the Commission on July 30, 2025;
|
(c) |
the Registrant’s Current Reports on Form 8-K filed with the Commission on March 12, 2025, May 19, 2025, June 10, 2025 and June 12,
2025; and
|
(d) |
the description of the Registrant’s Common Stock contained in the Registrant’s registration statement on Form 8-A filed with the SEC on April 12, 1991, as updated by its Certificate of Amendment of its Restated Certificate of Incorporation
filed with its Definitive Proxy Statement on Schedule 14A filed on April 25, 2014, and its Certificate of Amendment of its Restated Certificate of
Incorporation filed with its current report on Form 8-K filed on December 18, 2015.
|
Item 5. |
Interests of Named Experts and Counsel.
|
Item 6. |
Indemnification of Directors and Officers.
|
Item 8. |
Exhibits.
|
Exhibit Number
|
Description
|
|
4.1
|
Amended and Restated Certificate of Incorporation (1).
|
|
4.2
|
Certificate of Amendment to Restated Certificate of Incorporation (2).
|
|
4.3
|
Certificate of Amendment to Restated Certificate of Incorporation (3).
|
|
4.4
|
Amended and Restated Bylaws (4).
|
|
4.5
|
Certificate of Designation of the Series C Junior Participating Preferred Stock (5).
|
|
4.6
|
Specimen Common Stock Certificate (6).
|
|
Opinion of Patrick R. O’Neil.
|
||
Consent of Independent Registered Public Accounting Firm.
|
||
Consent of Patrick R. O’Neil. Reference is made to Exhibit 5.1.
|
||
Power of Attorney is contained on the signature pages.
|
||
99.1
|
Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (7).
|
|
99.2
|
Form of Option Agreement for Options granted under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (8).
|
|
99.3
|
Form of Time-Vested Restricted Stock Unit Agreement for Restricted Stock Units granted under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (9).
|
|
99.4
|
Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted prior to January 1,
2023 under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (10).
|
|
99.5
|
Forms of Performance Based Restricted Stock Unit Grant Notice and Performance Based Restricted Stock Unit Agreement for Performance Based Restricted Stock Units granted beginning January 1,
2023 under the Amended and Restated Ionis Pharmaceuticals, Inc. 2011 Equity Incentive Plan (11).
|
|
Filing Fee Table.
|
(1) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017, and incorporated herein by reference.
|
(2) |
Filed as an appendix to the Registrant’s Notice of 2014 Annual Meeting of Stockholders and Proxy Statement filed on April 25, 2014, and incorporated herein by reference.
|
(3) |
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed December 18, 2015, and incorporated herein by reference.
|
(4) |
Filed as an exhibit to the Registrant’s Current Report on Form 8-K filed March 29, 2021, and incorporated herein by reference.
|
(5) |
Filed as an exhibit to Registrant’s Current Report on Form 8-K filed December 13, 2000, and incorporated herein by reference.
|
(6) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2017, and incorporated herein by reference.
|
(7) |
Filed as an appendix to the Registrant’s Notice of 2025 Annual Meeting of Stockholders and Proxy Statement filed with the SEC on April 25, 2025, and incorporated herein by reference.
|
(8) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year December 31, 2022, filed with the SEC on February 22, 2023, and incorporated herein by reference.
|
(9) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year December 31, 2022, filed with the SEC on February 22, 2023, and incorporated herein by reference.
|
(10) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2021, and incorporated herein by reference.
|
(11) |
Filed as an exhibit to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2022, and incorporated herein by reference.
|
Item 9. |
Undertakings.
|
Ionis Pharmaceuticals, Inc.
|
||
By:
|
/s/ Brett Monia
|
|
Brett Monia
|
||
Chief Executive Officer
|
Signature
|
Title
|
Date
|
/s/ Brett Monia
|
Chief Executive Officer
(Principal Executive Officer)
|
July 30, 2025
|
Brett Monia
|
||
/s/ Elizabeth Hougen
|
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
July 30, 2025
|
Elizabeth Hougen
|
||
/s/ Joseph Loscalzo
|
Chairman of the Board
|
July 30, 2025
|
Joseph Loscalzo
|
||
/s/ Spencer R. Berthelsen
|
Director
|
July 30, 2025
|
Spencer R. Berthelsen
|
||
/s/ Allene Diaz
|
Director
|
July 30, 2025
|
Allene Diaz
|
||
/s/ Michael Hayden
|
Director
|
July 30, 2025
|
Michael Hayden
|
||
/s/ Joan Herman
|
Director
|
July 30, 2025
|
Joan Herman
|
/s/ Joseph Klein, III
|
Director
|
July 30, 2025
|
Joseph Klein, III
|
||
/s/ B. Lynne Parshall
|
Director
|
July 30, 2025
|
B. Lynne Parshall
|
||
/s/ Joseph Wender
|
Director
|
July 30, 2025
|
Joseph Wender
|
||
/s/ Michael Yang
|
Director
|
July 30, 2025
|
Michael Yang
|